Skip to main content

Table 2 Charlson comorbidity index in treatment and control groups (M ± SD or number of cases)

From: Efficacy of the Essential Amino Acids and Keto-Analogues on the CKD progression rate in real practice in Russia - city nephrology registry data for outpatient clinic

  Treatment group Control group p
Charlson comorbidity index 4,91 ± 1,67 5,09 ± 1,58 0,59
Myocardial infarction 8 9 0,73
Congestive heart failure 24 28 0,37
Peripheral disease 43 36 0,14
Cerebrovascular disease 28 24 0,35
Dementia 3 6 0,21
Chronic pulmonary disease 9 13 0,23
Connective tissue disease 2 5 0,17
Peptic ulcer disease 13 19 0,12
Mild liver disease 11 18 0,07
Diabetes without end-organ damage 10 11 0,75
Hemiplegia 4 2 0,15
Moderate or severe renal disease 96 96
Diabetes with end-organ damage 2 3 0,56
Tumor without metastasis 4 3 0,61
Leukemia 1 1
Lymphoma 1 1
Moderate or severe liver disease 3 4 0,61
Metastatic solid tumor 0 0
AIDS 0 0